Tres Alchemix Overview
- Year Founded
-
2023
- Status
-
Private
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$4.4M
- Investors
-
2
Tres Alchemix General Information
Description
Developer of an AI-powered biotechnology platform designed to build human in silico models that can predict the efficacy and safety of new compounds. The company's platform integrates multimodal and multi-omics data with proprietary quantum chemistry calculations to predict drug pharmacokinetics and pharmacodynamics and analyze how chemicals behave within cells, tissues, and the human body, enabling clients to make the complexity of the human body interpretable.
Contact Information
Website
www.tresalchemix.comCorporate Office
- Room 312, Tokan Hakata, 5th Building
- 2-19-17 Hakata Ekimae, Hakata-ku
- Fukuoka
- Japan
Corporate Office
- Room 312, Tokan Hakata, 5th Building
- 2-19-17 Hakata Ekimae, Hakata-ku
- Fukuoka
- Japan
Tres Alchemix Timeline
Tres Alchemix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 26-Sep-2025 | $4.4M | Completed | Generating Revenue | ||
| 1. Seed Round | 16-Aug-2023 | Completed | Generating Revenue |
Tres Alchemix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Start-up investment stock |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Tres Alchemix Patents
Tres Alchemix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025197052-A1 | Molecule analysis system, program, and molecule analysis method | Pending | 22-Mar-2024 | ||
| EP-4629144-A1 | Prediction device, prediction method, and prediction program | Pending | 30-Nov-2022 | ||
| EP-4629144-A4 | Prediction device, prediction method, and prediction program | Pending | 30-Nov-2022 | ||
| JP-2025134955-A | Prediction device, prediction method, and prediction program | Pending | 30-Nov-2022 | ||
| JP-7706817-B2 | Prediction device, prediction method, and prediction program | Active | 30-Nov-2022 | G06N20/00 |
Tres Alchemix Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| DNX Ventures | Venture Capital | Minority | ||
| Waseda University Ventures | Venture Capital | Minority |
Tres Alchemix FAQs
-
When was Tres Alchemix founded?
Tres Alchemix was founded in 2023.
-
Where is Tres Alchemix headquartered?
Tres Alchemix is headquartered in Fukuoka, Japan.
-
What industry is Tres Alchemix in?
Tres Alchemix’s primary industry is Biotechnology.
-
Is Tres Alchemix a private or public company?
Tres Alchemix is a Private company.
-
What is the current valuation of Tres Alchemix?
The current valuation of Tres Alchemix is .
-
What is Tres Alchemix’s current revenue?
The current revenue for Tres Alchemix is .
-
How much funding has Tres Alchemix raised over time?
Tres Alchemix has raised $5.8M.
-
Who are Tres Alchemix’s investors?
DNX Ventures and Waseda University Ventures have invested in Tres Alchemix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process